EAM
JAZZ icon

Empirical Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Empirical Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-43,520
Closed -$43.5K – 381
2024
Q4 		$43.5K Buy
+43,520
New +$5.13M 0.01% 387

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Empirical Asset Management's JAZZ Position: Q1 2025 in Review

Empirical Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2025, closing a stake of 43,520 shares — an estimated $43.5K sold.

Empirical Asset Management first reported a position in JAZZ in Q4 2024 and held it in 1 quarter. The position peaked at $43.5K in Q4 2024. 550 funds tracked by Wall St. Rank hold JAZZ as of Q1 2025.

  • Empirical Asset Management reported no remaining Jazz Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Empirical Asset Management sold 43,520 Jazz Pharmaceuticals shares in Q1 2025, an estimated $43.5K.
  • Empirical Asset Management first reported a position in Jazz Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Empirical Asset Management's Jazz Pharmaceuticals position peaked at $43.5K in Q4 2024.
  • 550 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2025.

Based on Empirical Asset Management's 13F filing for Q1 2025, filed 12 May 2025.